Literature DB >> 1628386

Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation.

Z Wang1, P Pagé, S Nattel.   

Abstract

Class Ic antiarrhythmic drugs are effective in the treatment of atrial fibrillation, but their mechanism of action is unknown. In previous work, we have found that flecainide causes tachycardia-dependent increases in atrial action potential duration (APD) and effective refractory period (ERP) by reducing APD accommodation to heart rate. The present study was designed to evaluate the efficacy and mechanisms of action of flecainide in an experimental model of sustained atrial fibrillation (AF). AF was produced by a brief burst of atrial pacing in the presence of vagal stimulation and persisted spontaneously until vagal stimulation was stopped. The actions of flecainide at two dose levels were compared with those of isotonic glucose placebo in each dog, with a randomized order of blinded drug administration. Flecainide terminated AF in all 16 dogs, while glucose was effective in none (p less than 0.0001). Flecainide increased atrial ERP and reduced conduction velocity in a tachycardia-dependent manner. Doses of flecainide that converted AF resulted in larger changes in ERP than in conduction velocity, increasing the minimum path-length capable of supporting reentry (wavelength). In addition, flecainide reduced regional heterogeneity in ERP and wavelength, an action opposite that of vagal stimulation. Atrial epicardial mapping with a 112-electrode atrial array was used to study the mechanism of flecainide action on AF. Under control conditions, multiple small zones of reentry coexisted. Flecainide progressively increased the size of reentry circuits, decreased their number, and slowed the frequency of atrial activation until the arrhythmia finally terminated; all changes were compatible with an increase in wavelength. We conclude that flecainide terminates atrial fibrillation in this experimental model by causing tachycardia-dependent increases in atrial ERP, which increase the wavelength at the rapid rates characteristic of AF to the point that the arrhythmia can no longer sustain itself.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1628386     DOI: 10.1161/01.res.71.2.271

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  27 in total

1.  Electrophysiological heterogeneity of atrial fibrillation and local effect of propafenone in the human right atrium: analysis based on symbolic dynamics.

Authors:  A Berkowitsch; J Carlsson; A Erdogan; J Neuzner; H F Pitschner
Journal:  J Interv Card Electrophysiol       Date:  2000-06       Impact factor: 1.900

2.  Effect of phenylephrine infusion on atrial electrophysiological properties.

Authors:  J W Leitch; M Basta; P J Fletcher
Journal:  Heart       Date:  1997-08       Impact factor: 5.994

3.  Effects of propafenone on K currents in human atrial myocytes.

Authors:  A Seki; N Hagiwara; H Kasanuki
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

Review 4.  Improving Atrial Fibrillation Therapy: Is There a Gene for That?

Authors:  William J Hucker; Alan Hanley; Patrick T Ellinor
Journal:  J Am Coll Cardiol       Date:  2017-04-25       Impact factor: 24.094

Review 5.  Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy.

Authors:  Peng-Sheng Chen; Lan S Chen; Michael C Fishbein; Shien-Fong Lin; Stanley Nattel
Journal:  Circ Res       Date:  2014-04-25       Impact factor: 17.367

6.  Device-based autonomic modulation in arrhythmia patients: the role of vagal nerve stimulation.

Authors:  William A Huang; Kalyanam Shivkumar; Marmar Vaseghi
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-05

7.  Transient ST Elevation in Vagally Mediated Atrial Fibrillation.

Authors:  Constantinos Makrides
Journal:  J Atr Fibrillation       Date:  2012-06-15

8.  Pilot study: Noninvasive monitoring of oral flecainide's effects on atrial electrophysiology during persistent human atrial fibrillation using the surface electrocardiogram.

Authors:  Daniela Husser; Karl-Heinz Binias; Martin Stridh; Leif Sornmo; S Bertil Olsson; Jochen Molling; Christoph Geller; Helmut U Klein; Andreas Bollmann
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-04       Impact factor: 1.468

9.  Mechanisms by Which Ranolazine Terminates Paroxysmal but Not Persistent Atrial Fibrillation.

Authors:  Rafael J Ramirez; Yoshio Takemoto; Raphaël P Martins; David Filgueiras-Rama; Steven R Ennis; Sergey Mironov; Sandesh Bhushal; Makarand Deo; Sridharan Rajamani; Omer Berenfeld; Luiz Belardinelli; José Jalife; Sandeep V Pandit
Journal:  Circ Arrhythm Electrophysiol       Date:  2019-10-09

10.  Impact of baseline atrial fibrillation cycle length on acute and long-term outcome of persistent atrial fibrillation ablation.

Authors:  S Ammar; G Hessling; M Paulik; T Reents; R Dillier; A Buiatti; V Semmler; C Kolb; B Haller; I Deisenhofer
Journal:  J Interv Card Electrophysiol       Date:  2014-07-10       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.